Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 207 participants.
Also called NCT02725372
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 207 participants
- Registry
-
NCT02725372
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Canada, Colombia, Croatia, Czechia, France, Germany, Israel, Italy, Netherlands, Portugal, Serbia, Spain, Ukraine, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT02725372. Randomized; quadruple masking; primary purpose treatment. Start 2016-04 (actual); primary completion 2018-08 (actual). Results posted on 2023-01-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
- Acronym
- INOvation-1
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Inhaled Nitric Oxide 75 mcg/kg IBW/hr
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bellerophon Pulse Technologies
- Collaborator
- Worldwide Clinical Trials
Record details
- Record id
cardio:ct-nct02725372- Content hash
11df83d5d9bd51347dc14ad5ddf1aabbb277e771483302bab1986da9cc1dfbae